Challenges and Impact of Conducting Vaccine Trials in Africa and Asia

  Sonali Kochhar, M.D. Clinical Research and Drug Developmental Specialist, PATH joined us at the World Vaccine Congress Lyon 2012  to discuss the challenges and impact of conducting of vaccine trials in Africa and Asia. Clinical Research in Developing Countries is limited due to the climate under which the vaccine industry has to work in Developing Countries- a climate characterised …

NEW APPROACHES FOR ADJUVANT DEVELOPMENT IN PROPHYLACTIC VACCINES

NEW APPROACHES FOR ADJUVANT DEVELOPMENT IN PROPHYLACTIC VACCINES Dr Else Marie Agger, Head of Research, SSI joined us at the World Vaccine Congress Lyon 2012 to lead a discussion into new approaches for adjuvant development in prophylactic vaccines. Why not download the full presentation and discover more about new approaches for vaccine adjuvants development in prophylactic vaccines. Dr Agger's covered …

World Vaccine Congress Europe 2013

Are you looking to: Align with global vaccine strategies Get approval for new vaccines Take advantage of breakthrough vaccine technology Enhance next generation vaccines Expand their vaccine pipelines and geography Develop new Partnering & Collaboration relationships Speed their route through the clinic Prepare for product pre-qualification Unlock data management efficiencies Implement cost effective production Increase capacity and yield Adopt lean …

World Vaccine Congress Europe 2013

The World Vaccine Congress & Expo brings together vaccine leaders and policy makers Do you want to raise your profile within the largest R&D vaccine community? Are you looking for the opportunity to educate the market about your offering? Do you want to gain market share by positioning yourself as a leader? Do you need to meeting qualified buyers? Benefit …

Live event feed: Dr. Harriet Robinson

Dr. Harriet L. Robinson, Chief Scientific Officer at GeoVax Inc., a biotech company specializing in the development of HIV/AIDS vaccines, has multi-protein clade B DNA/MVA and MVA/MVA vaccine regimens in clinical trials through the US HIV vaccine Trials Network (HVTN). The vaccine was developed in Dr. Robinson's former laboratory at the Emory Vaccine Center in collaboration with Dr. Bernard Moss's …

Live event feed: Dr. Rod Hafner

Dr. Rod Hafner is Senior Vice President of R&D at Circassia Ltd. where he has overall responsibility for Circassia's R&D portfolio. Since joining Circassia in 2007 Dr. Hafner has been responsible for the progression of Circassia's four lead programmes from epitope identification, through to the start of twelve phase II clinical studies. Following a Ph.D. in Biochemistry at Cambridge University …

Live event feed: Peter Keller

Blogged on behalf of Natalia Forero Serna Broadening your pipeline & balancing your portfolio Peter Keller, Vice President Business Development, Selecta Biosciences presented today at the World Vaccine Congress Lyon to detail how to broaden your pipeline and balance your portfolio. As an expert from Selecta Biosciences he gave details on applications for Synthetic Vaccine Particle (SVP) technology, Selecta's portfolio …

Live event feed: Dr. Cécile Bauche

Dr Bauche holds a PhD in molecular biology and biochemistry and a Magistère in human genetics and biostatistics (Paris VII). During her previous experience with Institut Pasteur (VACACT european project) and Ecole Normale Supérieure (CLINIGENE network of excellence), she led scientific projects and international collaborations in the fields of therapeutic proteins and viral vector engineering. Since 2007, she leads Theravectys' …

Live event feed: Dr Thomas Fuerst

Blogged on behalf of Natalia Forero Serna Dr Thomas Fuerst, Executive Vice President, Chief Scientific Officer, PharmAthene presented today at the World Vaccine Congress Lyon to give details on the development of a robust manufacturing platform for production of a next generation anthrax vaccine. The production of this vaccine will be achieved through the use of modern vaccine production technologies …